ENTA News and Press, Enanta Pharmaceuticals Inc. From 08/04/20

Initiated Phase 1b Study of EDP-514 in Viremic HBV Patients and Resumed Phase 1b Study of EDP-514 in NUC-Suppressed HBV Patients; Preliminary Data Expected in 1H 2021 and 2Q 2021, Respectively Plans to Initiate Two Phase 2 Studies of EDP-938 in Pediatric and Adult Transplant Patient...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the BTI...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2020 after the U.S. ...

Enanta Pharmaceuticals (NASDAQ: ENTA ) advances its hepatitis B virus (HBV) program evaluating EDP-514 across different patient populations. More news on: Enanta Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Initiated Phase 1b Study Evaluating EDP-514 in Viremic HBV Patients; Preliminary Data Anticipated in 1H 2021 Resumed Phase 1b Study Assessing Safety and Antiviral Activity of EDP-514 in NUC-Suppressed HBV Patients; Topline Results Anticipated in 2Q 2021 Enanta Pharmaceuticals...

Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test now using the top four forensic algorithms applied to detect bankruptcy risk, earnings manipulation, and financial irregularities. This forward testing study co...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Mark G. Foletta to its Board of Directors. Mr. Foletta will also serve as the Chair of the ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Raymond James Human Health...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 202...

Moderna Receives FDA Approval for Phase 2 Studies, Reports Q1 Results Moderna (MRNA) reported that the FDA has given approval for the start of Phase 2 trial of its Coronovirus vaccine, mRNA-1273. The company is now looking to begin the trial at the earliest. Moderna also reported its Q1 f...